Feedback on draft medication alert – ‘Alteplaseor tenecteplase?’
Please return completed form to Beth Loeby 5pm, 15 July 2016, either via including ‘draft alert feedback’ in the subject line, or by post:
Beth Loe, Health Quality & Safety Commission, Private Bag 92 522, Auckland 1141.
Your role
Your email address
Contact phone number
Are you commenting as an individual? / ☐Yes ☐No
If ‘No’, name of organisation you represent
We are particularly interested in your comments on required actions 1, 3 and 4:
1.Required action 1: Have a current stroke thrombolysis clinical pathway, guideline or protocolreadily available in the hospital with suggested inclusions.
Do you agree with the inclusions list and/or do you have other suggestions (with reasons) for inclusions?
Any other comments?
2.Required action 3: Ensure a stroke kit clearly labelled for stroke thrombolysis is available in the hospital area(s) where this is carried out with a list of minimum inclusions.
Do you agree that stroke kit(s) are necessary in hospital areas where stroke thrombolysis is carried out?
If you do not agree, can you propose different actions to prevent the risk of inadvertent use of tenecteplase for stroke thrombolysis?
If a stroke kit is or will be available in your hospital, are there things you think should be added to:
- the minimal list?
- the optional inclusions?
3.Required action 4: Ensure a myocardial infarction thrombolysis kit clearly labelled for myocardial infarction thrombolysis is available in the hospital area(s) where there is a possibility stroke thrombolysis could be carried out with a list of minimal inclusions.
Do you agree a myocardial infarction thrombolysis kit is necessary in areas where both stroke and myocardial infarction thrombolysis could occur?
If you do not agree can you propose different actions to prevent the risk of inadvertent use of tenecteplase for stroke thrombolysis?
Should a myocardial infarction thrombolysis clinical pathway,guideline or protocol be available in the kit?
If a myocardial infarction thrombolysis kit is or will be available in your hospital, are there things you think should be added:
- to the minimal list?
- to an optional inclusions list?
Please also give us your comments on required actions 2 and 5:
4.Comments on action 2: Check all clinical pathways, guidelines and protocols that include thrombolysis describe in full which thrombolytic to use, for example, alteplase or tenecteplase. Never use abbreviations, such as tpa, to describe these medicines.
5.Comments on action 5: Establish a reliable process for managing both kits, including refilling, ongoing content checks for expiry and use, and review of the contents.
6.Do you or your organisation have any further comments on required actions 1–5? If so, please specify.
7.Are there any further actions that should be required to reduce the risks associated with stroke thrombolysis?
Please provide optional comments on other sections of the draft alert. You can also send an annotated scan of the draft alert as feedback if you wish.
8.Comments on other sections of the alert:
1